Drug intelligence / Profile preview

ADX-199

Development stage: Preclinical
Lead developer: ADARx Pharmaceuticals
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

ADX-199 is an investigational small interfering RNA (siRNA) therapeutic being developed by ADARx Pharmaceuticals for the treatment of neurodegenerative diseases. Utilizing ADARx's proprietary RNA targeting platform, ADX-199 is designed to silence a specific mRNA transcript involved in the pathogenesis of neurodegeneration. While the exact molecular target has not been publicly disclosed, the drug represents ADARx's expansion into central nervous system (CNS) disorders, leveraging their expertise in RNA interference to address unmet needs in neurodegenerative conditions.

Beyond the preview

Go deeper on ADX-199.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADX-199.

Explore the full profile